Retreatment with progestin for recurrence after complete response with fertility-sparing treatment in patients with endometrial cancer

A Jin Lee; Seung-Hyuk Shim; Nae Ry Kim; Eun Jung Yang; Kyeong A So; Sun Joo Lee; Ji Young Lee; Tae Jin Kim; Soon-Beom Kang

doi:10.1136/ijgc-2022-003546

Retreatment with progestin for recurrence after complete response with fertility-sparing treatment in patients with endometrial cancer

Int J Gynecol Cancer. 2022 Jun 24:ijgc-2022-003546. doi: 10.1136/ijgc-2022-003546. Online ahead of print.

Authors

A Jin Lee¹, Seung-Hyuk Shim², Nae Ry Kim¹, Eun Jung Yang¹, Kyeong A So¹, Sun Joo Lee¹, Ji Young Lee¹, Tae Jin Kim¹, Soon-Beom Kang³

Affiliations

¹ Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea.
² Department of Obstetrics and Gynecology, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Republic of Korea nastassja@hanmail.net.
³ Hosan Women's Hospital, Seoul, Republic of Korea.

PMID: 35750352
DOI: 10.1136/ijgc-2022-003546

Abstract

Objective: To assess the outcomes of retreatment using progestin for recurrence after a complete response with fertility-sparing treatment in patients with early endometrial cancer.

Methods: We retrospectively reviewed the data of patients with presumed stage IA, grade 1 endometrioid endometrial cancer who developed intra-uterine recurrence after a complete response with fertility-sparing treatment using progestin. Oncological and pregnancy outcomes were analyzed after repeated fertility-sparing treatment. Logistic and Cox regression analyses were performed to analyze the prognostic factors associated with a complete response with secondary fertility-sparing treatment and recurrence-free survival after secondary fertility-sparing treatment, respectively.

Results: Fifty patients with a median age of 31 years (range 23-40) underwent secondary fertility-sparing treatment. With a median secondary progestin treatment duration of 9 months (range 3-55), the complete response rate was 78% (39/50) and no patients had extra-uterine spread of disease. Among the 26 (67%) patients who attempted to conceive after complete response, 10 became pregnant (3 spontaneous abortions, 7 live births). Eighteen (46.1%) patients had a second recurrence, with a median recurrence-free survival after secondary fertility-sparing treatment of 14 months (range 3-36); 15 patients received tertiary fertility-sparing treatment and nine (60%) achieved a complete response. Polycystic ovary on ultrasound (OR 5.82, 95% CI 1.1 to 30.6, p=0.037) was associated with an increased complete response rate with secondary fertility-sparing treatment. Multivariable analysis revealed that recurrence-free survival after initial hormonal treatment >6 months (HR 0.11, 95% CI 0.02 to 0.51, p=0.005) and pregnancy after secondary fertility-sparing treatment (HR 0.27, 95% CI 0.08 to 0.98; p=0.047) were significantly associated with longer recurrence-free survival after secondary fertility-sparing treatment.

Conclusions: Repeated progestin treatment was associated with a 78% response rate and it was safe in patients with intra-uterine recurrent endometrial cancer. Thus, it might help preserve fertility after first and second recurrences.

Keywords: Endometrial Neoplasms.